Healthcare
Exclusive insider sentiment analysis for the Healthcare sector. Track real-time Director purchases and institutional money flow to identify high-conviction opportunities before the market reacts.
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-03 20:30 | 2026-04-01 | NUVL | Nuvalent, Inc. | Balcom Alexandra | Officer; Chief Financial Officer | Biotechnology | OPT+S | $105.21 | 11,430 | $1,202,526 | 85,533 | -11.8% |
| 2026-04-03 20:53 | 2026-04-01 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Liu Joy | Officer; EVP and Chief Legal Officer | Biotechnology | SALE | $449.17 | 978 | $439,288 | 21,833 | -4.3% |
| 2026-04-03 20:10 | 2026-04-01 | DYN | Dyne Therapeutics, Inc. | Lucera Erick | Officer; Chief Financial Officer | Biotechnology | SALE | $18.64 | 5,727 | $106,751 | 125,373 | -4.4% |
| 2026-04-03 20:24 | 2026-04-01 | TECX | Tectonic Therapeutic, Inc. | Ruddy Marcella K. | Officer; Chief Medical Officer | Biotechnology | SALE | $31.05 | 1,000 | $31,050 | 68,747 | -1.4% |
| 2026-04-03 20:12 | 2026-04-01 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Officer; CHIEF MEDICAL OFFICER | Biotechnology | SALE | $32.66 | 1,838 | $60,029 | 38,864 | -4.5% |
| 2026-04-03 20:00 | 2026-04-01 | TWST | Twist Bioscience Corp | Starovasnik Melissa A. | Director | Diagnostics & Research | SALE | $51.00 | 1,000 | $51,000 | 25,722 | -3.7% |
| 2026-04-03 20:28 | 2026-04-02 | SGHT | Sight Sciences, Inc. | Bauerlein Alison | Officer; Chief Operating Officer | Medical Devices | SALE | $3.48 | 25,874 | $90,042 | 701,621 | -3.6% |
| 2026-04-03 20:28 | 2026-04-02 | SGHT | Sight Sciences, Inc. | Badawi David | Director, Officer; Chief Technology Officer | Medical Devices | SALE | $3.48 | 8,168 | $28,425 | 1,990,290 | -0.4% |
| 2026-04-03 20:27 | 2026-04-01 | SGHT | Sight Sciences, Inc. | Taylor Brenton | Officer; EVP, Operations & R&D | Medical Devices | SALE | $3.70 | 2,869 | $10,615 | 267,807 | -1.1% |
| 2026-04-03 20:27 | 2026-04-01 | SGHT | Sight Sciences, Inc. | Badawi Paul | Director, Officer, 10% owner; President and CEO | Medical Devices | SALE | $3.70 | 29,244 | $108,203 | 6,151,156 | -0.5% |
| 2026-04-03 19:58 | 2026-04-02 | TDOC | Teladoc Health, Inc. | Catapano Joseph Ronald | Officer; Chief Accounting Officer | Health Information Services | OPT+S | $5.11 | 675 | $3,452 | 10,249 | -6.2% |
| 2026-04-03 20:07 | 2026-04-01 | BIOA | BioAge Labs, Inc. | RUBIN PAUL D | Officer; Chief Medical Officer | Drug Manufacturers - Specialty & Generic | OPT+S | $17.81 | 8,820 | $157,084 | 0 | -100.0% |
| 2026-04-03 20:01 | 2026-04-01 | REGN | REGENERON PHARMACEUTICALS, INC. | RYAN ARTHUR F | Director | Biotechnology | SALE | $777.27 | 100 | $77,727 | 17,603 | -0.6% |
| 2026-04-03 21:00 | 2026-04-02 | CAPR | CAPRICOR THERAPEUTICS, INC. | Sabar Karimah Es | Director | Biotechnology | OPT+S | $32.00 | 7,529 | $240,928 | 0 | -100.0% |
| 2026-04-03 20:07 | 2026-04-01 | INSM | INSMED Inc | Adsett Roger | Officer; Chief Operating Officer | Biotechnology | OPT+S | $164.63 | 88,060 | $14,497,652 | 106,810 | -45.2% |
| 2026-04-04 01:29 | 2026-04-01 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | Officer; Chief Financial Officer | Biotechnology | OPT+S | $49.34 | 7,500 | $370,076 | 97,994 | -7.1% |
| 2026-04-04 01:30 | 2026-04-01 | SYRE | Spyre Therapeutics, Inc. | Sloan Sheldon | Officer; Chief Medical Officer | Biotechnology | OPT+S | $50.00 | 7,958 | $397,900 | 0 | -100.0% |
| 2026-04-04 01:30 | 2026-04-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | Director, Officer; Chief Executive Officer | Biotechnology | SALE | $49.33 | 15,000 | $739,913 | 627,540 | -2.3% |
| 2026-04-04 01:05 | 2026-04-01 | NTRA | Natera, Inc. | Moshkevich Solomon | Officer; PRESIDENT, CLINICALDIAGNOSTICS | Diagnostics & Research | SALE | $202.30 | 3,000 | $606,899 | 147,882 | -2.0% |
| 2026-04-04 01:05 | 2026-04-01 | NTRA | Natera, Inc. | RABINOWITZ DANIEL | Officer; SEC. AND CHIEF LEGAL OFFICER | Diagnostics & Research | SALE | $203.31 | 8,400 | $1,707,814 | 224,885 | -3.6% |
| 2026-04-04 00:00 | 2026-04-01 | APGE | Apogee Therapeutics, Inc. | Henderson Jane | Officer; Chief Financial Officer | Biotechnology | SALE | $85.01 | 2,000 | $170,020 | 177,371 | -1.1% |
| 2026-04-04 00:00 | 2026-04-01 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Officer; Chief Medical Officer | Biotechnology | OPT+S | $84.84 | 5,500 | $466,619 | 208,398 | -2.6% |
| 2026-04-03 23:46 | 2026-04-02 | IMNM | Immunome Inc. | Rosett Max | Officer; Chief Financial Officer | Biotechnology | OPT+S | $21.92 | 65,000 | $1,424,917 | 54,037 | -54.6% |
| 2026-04-03 23:48 | 2026-04-02 | IMNM | Immunome Inc. | Higgins Jack | Officer; Chief Scientific Officer | Biotechnology | SALE | $21.64 | 9,438 | $204,238 | 22,000 | -30.0% |
| 2026-04-03 22:09 | 2026-04-01 | SIBN | SI-BONE, Inc. | PISETSKY MICHAEL A. | Officer; SVP, Ops & Adm/Chief Legal Ofr | Medical Devices | SALE | $12.91 | 3,134 | $40,466 | 282,840 | -1.1% |
| 2026-04-03 22:11 | 2026-04-02 | SIBN | SI-BONE, Inc. | Maheshwari Anshul | Officer; Chief Financial Officer | Medical Devices | SALE | $12.87 | 3,318 | $42,708 | 263,148 | -1.2% |
| 2026-04-03 22:15 | 2026-04-01 | HTFL | Heartflow, Inc. | Rogers Campbell | Officer; Chief Medical Officer | Health Information Services | OPT+S | $24.64 | 64,533 | $1,590,093 | 81,002 | -44.3% |
| 2026-04-03 22:17 | 2026-04-02 | WHWK | Whitehawk Therapeutics, Inc. | Lennon David James | Director, Officer; CHIEF EXECUTIVE OFFICER | Biotechnology | OPT+S | $3.48 | 26,858 | $93,466 | 793,549 | -3.3% |
| 2026-04-03 21:55 | 2026-04-02 | VYGR | Voyager Therapeutics, Inc. | Sandrock Alfred | Director, Officer; President and CEO | Biotechnology | SALE | $3.87 | 11,511 | $44,548 | 472,549 | -2.4% |
| 2026-04-03 21:57 | 2026-04-02 | ZLAB | Zai Lab Ltd | Amado Rafael | Officer; See Remarks | Biotechnology | OPT+S | $20.39 | 9,910 | $202,065 | 59,761 | -14.2% |
| 2026-04-03 21:57 | 2026-04-02 | ZLAB | Zai Lab Ltd | Chen Yajing | Officer; Chief Financial Officer | Biotechnology | OPT+S | $20.39 | 5,199 | $106,008 | 32,558 | -13.8% |
| 2026-04-03 21:58 | 2026-04-02 | ZLAB | Zai Lab Ltd | Du Ying | Director, Officer; Chairperson & CEO | Biotechnology | OPT+S | $20.39 | 5,576 | $113,695 | 1,125,279 | -0.5% |
| 2026-04-03 21:58 | 2026-04-02 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | Officer; Chief Legal Officer | Biotechnology | OPT+S | $20.39 | 4,194 | $85,516 | 24,590 | -14.6% |
| 2026-04-03 21:59 | 2026-04-02 | ZLAB | Zai Lab Ltd | Smiley Joshua L | Officer; See Remarks | Biotechnology | OPT+S | $20.39 | 9,614 | $196,029 | 120,619 | -7.4% |
| 2026-04-03 21:45 | 2026-04-01 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | Officer; See Remarks | Biotechnology | SALE | $5.99 | 16,667 | $99,859 | 1,209,840 | -1.4% |
| 2026-04-03 21:46 | 2026-04-01 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Director | Biotechnology | SALE | $23.88 | 10,000 | $238,801 | 39,744 | -20.1% |
| 2026-04-03 21:09 | 2026-04-01 | JAZZ | Jazz Pharmaceuticals plc | COZADD BRUCE C | Director | Biotechnology | SALE | $190.50 | 6,000 | $1,143,010 | 384,682 | -1.5% |
| 2026-04-03 21:20 | 2026-04-01 | PTCT | PTC THERAPEUTICS, INC. | Almstead Neil Gregory | Officer; CHIEF TECHNICAL OPS OFFICER | Biotechnology | SALE | $69.04 | 52,003 | $3,590,240 | 60,137 | -46.4% |
| 2026-04-03 21:06 | 2026-04-02 | ANVS | Annovis Bio, Inc. | Hoffman Michael B | Director | Biotechnology | BUY | $2.10 | 713,800 | $1,498,980 | 3,288,539 | +27.7% |
| 2026-04-03 20:33 | 2026-04-02 | IMVT | Immunovant, Inc. | Venker Eric | Director, Officer; Chief Executive Officer | Biotechnology | OPT+S | $24.10 | 14,229 | $342,855 | 19,561 | -42.1% |
| 2026-04-03 20:05 | 2026-04-01 | PACB | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | Gibson James R II | Officer; See Remarks | Medical Devices | SALE | $1.37 | 88,185 | $120,813 | 1,245,663 | -6.6% |
| 2026-04-03 20:05 | 2026-04-01 | EBS | Emergent BioSolutions Inc. | Williams Paul Anthony | Officer; SVP, Products Business | Drug Manufacturers - Specialty & Generic | SALE | $8.44 | 4,000 | $33,760 | 62,681 | -6.0% |
| 2026-04-03 20:06 | 2026-04-01 | PCVX | Vaxcyte, Inc. | Wassil Jim | Officer; CHIEF OPERATING OFFICER | Biotechnology | SALE | $58.43 | 2,250 | $131,476 | 162,994 | -1.4% |
| 2026-04-03 19:13 | 2026-04-01 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Officer; Chief Medical Officer | Biotechnology | OPT+S | $16.00 | 679 | $10,864 | 3,622 | -15.8% |
| 2026-04-03 19:14 | 2026-04-01 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | Officer; Chief Financial Officer | Biotechnology | SALE | $16.96 | 15,959 | $270,593 | 17,338 | -47.9% |
| 2026-04-03 17:55 | 2026-04-01 | CBLL | Ceribell, Inc. | Woo Raymond | Officer; Chief Technology Officer | Medical Devices | OPT+S | $18.56 | 11,112 | $206,243 | 166,912 | -6.2% |
| 2026-04-03 15:23 | 2026-04-01 | NRXS | Neuraxis, INC | Henrichs Timothy Robert | Officer; Chief Financial Officer | Biotechnology | BUY | $1.96 | 7,593 | $14,882 | 7,593 | +100.0% |
| 2026-04-03 15:19 | 2026-04-01 | NRXS | Neuraxis, INC | Carrico Brian Allen | Director, Officer; Chief Executive Officer | Biotechnology | BUY | $1.96 | 8,060 | $15,798 | 348,178 | +2.4% |
| 2026-04-03 15:21 | 2026-04-01 | NRXS | Neuraxis, INC | Carrico Thomas Joeseph | Officer; CRO, CCO, CPO | Biotechnology | BUY | $1.96 | 667 | $1,307 | 331,903 | +0.2% |
| 2026-04-03 13:00 | 2026-04-01 | ERAS | Erasca, Inc. | Garner Ebun | Officer; Chief Legal Officer | Biotechnology | OPT+S | $16.40 | 80,000 | $1,312,000 | 25,076 | -76.1% |
Strategic Analysis
Analyzing insider transactions within the Healthcare sector provides critical insights into institutional sentiment. When multiple executives across different companies in the same industry exhibit similar buying patterns (cluster buying), it often signals an upcoming sector-wide recovery or undervalued market conditions.
Regulatory Transparency
Our platform tracks SEC Form 4 filings in real-time. We differentiate between routine option exercises and open-market purchases to give you a clear view of "Skin in the Game". Understanding the roles of Directors vs. 10% Owners helps prioritize signals that carry the most predictive weight.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.